AB-101 is an optimized universal NK cell therapy candidate designed for clinical use with tumor-targeted therapeutics First clinical program applying Artiva’s proprietary large-scale NK-cell manufacturing process for off-the-shelf cellular therapies SAN DIEGO, December 7, 2020 — Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to…
